Table 1.
Basic information of the included studies.
| Study | Year | Country | Diseases | Total (M/F) | Treatment types | Sample | Assay | Cut-off value | Follow-up (year) |
Outcome measures | Analysis type |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bieche7 | 2007 | France | Breast cancer | 48 | Surgery | Tissue | RT-PCR | NR | 10 | RFS | U |
| Cao8 | 2017 | China | NSCLC | 50 (14/36) | Surgery | Tissue | CBA kit | NR | ≥2 | PFS | U |
| Cheng9 | 2011 | China | GC | 116 (65/51) | Surgery | Tissue | IHC | Strong staining | 5 | OS | M |
| Miyake10 | 2016 | USA | UCB | 142 | Surgery | Tissue | IHC | IS | 10 | PFS | U |
| Xiang12 | 2015 | China | GC | 127 (92/35) | Surgery | Tissue | IHC | IS>97.2% | 7 | OS | M and U |
| Zhuo14 | 2018 | China | CRC | 276 (166/100) | Surgery | Tissue | IHC | IS4 | 5 | OS | M and U |
| Zhang15 | 2017 | China | ESCC | 141 (75/66) | Radio- chemotherapy |
Tissue | IHC | Strong staining | 3 | OS | M and U |
| Wang16 | 2017 | China | GC | 105 (71/34) | Surgery | Tissue | IHC | NR | ≥8 | OS | U |
| Kasashima17 | 2017 | Japan | GC | 264 (114/150) | Surgery | Tissue | IHC | IS>3 | 5 | OS | M |
| Wang18 | 2016 | China | GC | 100 (65/35) | Surgery | Tissue | IHC | IS3 | 5 | OS | M |
| Nakashima19 | 2015 | Japan | Bladder cancer | 175 (132/43) | Surgery | Urine | ELISA | 35 pg/mg | 4.5 | OS | M and U |
| Wei20 | 2015 | China | GC | 98 (62/36) | Surgery | Tissue | IHC | Strong staining | 5 | OS | U |
| Zhang21 | 2014 | China | CSCC | 292 (F) | NR | Serum | Luminex technology | <748.43 pg/ml | 3 | OS, DFS | M |
| Cao22 | 2014 | China | HCC | 48 (41/7) | Surgery | Tissue | IHC | Strong staining | >6 | OS | M |
| Chen23 | 2013 | China | HCC | 179 (160/19) | Surgery | Serum | Luminex technology | NR | 8 | DFS | U |
| Miyake24 | 2013 | USA | Bladder cancer | 142 | NR | Tissue | IHC | IS3 | 4 | OS, DFS | M and U |
| Lian25 | 2016 | China | Pancreatic cancer |
160 | Surgery | Tissue | IHC | IS3 | 5 | OS | M and U |
CRC: colorectal cancer; IHC: immunohistochemical method; IS: immunoreactivity score; OS: overall survival; M: multivariate analysis; U: univariate analysis; ESCC: esophageal squamous cell carcinoma; CRC: colorectal Cancer; ELISA: enzyme-linked immunoassay; NSCLC: non-small cell lung cancer; GC: gastric cancer; CBA kit: human proinflammatory chemokine panel (13-plex) (BioLegend, San Diego, CA); UCB: urothelial cancer of the bladder; CSCC: cervical squamous cell carcinoma; HCC: hepatocellular carcinoma; NR, not reported.